Advanced

Prognostic impact of COX-2 in non-small cell lung cancer: A comprehensive compartment-specific evaluation of tumor and stromal cell expression.

Mattsson, Johanna S M; Bergman, Bengt; Grinberg, Marianna; Edlund, Karolina; Marincevic, Millaray; Jirström, Karin LU ; Pontén, Fredrik; Hengstler, Jan G; Rahnenführer, Jörg and Karlsson, Mats G, et al. (2015) In Cancer Letters 356(2). p.837-845
Abstract
Cyclooxygenase-2 (COX-2) is an enzyme that has been extensively investigated as a prognostic marker in cancer. In non-small cell lung cancer (NSCLC) previous results regarding the prognostic impact of COX-2 expression are inconsistent. Therefore we evaluated the association between transcript levels and overall survival in nine publicly available gene expression data sets (total n = 1337) and determined in situ compartment-specific tumor and stromal cell protein expression in two independent cohorts (n = 616). Gene expression did not show any correlation with clinical parameters or with overall survival. Protein expression in tumor and stromal cells did not correlate with any clinical parameter or with overall survival in one of the... (More)
Cyclooxygenase-2 (COX-2) is an enzyme that has been extensively investigated as a prognostic marker in cancer. In non-small cell lung cancer (NSCLC) previous results regarding the prognostic impact of COX-2 expression are inconsistent. Therefore we evaluated the association between transcript levels and overall survival in nine publicly available gene expression data sets (total n = 1337) and determined in situ compartment-specific tumor and stromal cell protein expression in two independent cohorts (n = 616). Gene expression did not show any correlation with clinical parameters or with overall survival. Protein expression in tumor and stromal cells did not correlate with any clinical parameter or with overall survival in one of the analyzed cohorts, while a significant association of high stromal expression with longer survival was observed in both univariate and multivariate analysis in the other cohort. Stromal expression of COX-2 has not been separately evaluated in NSCLC previously and may be a subject of further investigation, whereas the presented findings from this comprehensive compartment specific evaluation clearly reject the hypothesis of COX-2 tumor cell expression having a prognostic value in NSCLC. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Cancer Letters
volume
356
issue
2
pages
837 - 845
publisher
Elsevier
external identifiers
  • pmid:25449785
  • wos:000348005500057
  • scopus:84919444431
ISSN
1872-7980
DOI
10.1016/j.canlet.2014.10.032
language
English
LU publication?
yes
id
8d453a0e-c1ea-4f87-bdb9-0c87f0507c63 (old id 4913298)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/25449785?dopt=Abstract
date added to LUP
2015-01-08 15:43:13
date last changed
2017-08-27 03:32:37
@article{8d453a0e-c1ea-4f87-bdb9-0c87f0507c63,
  abstract     = {Cyclooxygenase-2 (COX-2) is an enzyme that has been extensively investigated as a prognostic marker in cancer. In non-small cell lung cancer (NSCLC) previous results regarding the prognostic impact of COX-2 expression are inconsistent. Therefore we evaluated the association between transcript levels and overall survival in nine publicly available gene expression data sets (total n = 1337) and determined in situ compartment-specific tumor and stromal cell protein expression in two independent cohorts (n = 616). Gene expression did not show any correlation with clinical parameters or with overall survival. Protein expression in tumor and stromal cells did not correlate with any clinical parameter or with overall survival in one of the analyzed cohorts, while a significant association of high stromal expression with longer survival was observed in both univariate and multivariate analysis in the other cohort. Stromal expression of COX-2 has not been separately evaluated in NSCLC previously and may be a subject of further investigation, whereas the presented findings from this comprehensive compartment specific evaluation clearly reject the hypothesis of COX-2 tumor cell expression having a prognostic value in NSCLC.},
  author       = {Mattsson, Johanna S M and Bergman, Bengt and Grinberg, Marianna and Edlund, Karolina and Marincevic, Millaray and Jirström, Karin and Pontén, Fredrik and Hengstler, Jan G and Rahnenführer, Jörg and Karlsson, Mats G and Karlsson, Christina and Helenius, Gisela and Botling, Johan and Micke, Patrick and Gulyas, Miklos},
  issn         = {1872-7980},
  language     = {eng},
  number       = {2},
  pages        = {837--845},
  publisher    = {Elsevier},
  series       = {Cancer Letters},
  title        = {Prognostic impact of COX-2 in non-small cell lung cancer: A comprehensive compartment-specific evaluation of tumor and stromal cell expression.},
  url          = {http://dx.doi.org/10.1016/j.canlet.2014.10.032},
  volume       = {356},
  year         = {2015},
}